Decreased Expression of Protocadherin 20 is Associated with Poor Prognosis in Hepatocellular Carcinoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Dec 10

PMID 27935871

Citations 5

Authors

Yanqin Wu

Shuhui Zheng

Jiayan Yao

Minrui Li

Guang Yang

Ning Zhang

Shenghong Zhang

Bihui Zhong

Affiliations

Soon will be listed here.

Abstract

Recently, protocadherin 20 has been reported as a tumor suppressor gene in hepatocellular carcinoma (HCC); however, the prognostic value of protocadherin 20 in HCC remains unclear. Hence, the purpose of this study was to investigate the clinical and prognostic values of protocadherin 20 in HCC patients. The expression of protocadherin 20 was assessed by quantitative real-time polymerase chain reaction, western blot, and immunohistochemistry. Kaplan-Meier curves were created to calculate the overall survival of the patients, and Cox regression models were used to identify the risk factors associated with prognosis. Of 317 primary HCC patients, decreased expression of protocadherin 20 was observed in 184 (58.0%) patients (P < 0.001). Reduced protocadherin 20 protein expression correlated with portal hypertension, poor tumor differentiation, advanced Okuda stage, and Cancer of the Liver Italian Program score (all P < 0.05). Low protocadherin 20 expression was an independent risk factor for mortality (P = 0.018). Furthermore, in our newly developed simple risk score based on protocadherin 20, patients with total score > 1.11 showed significantly poorer outcome; and the predictive value of the score was better than the Barcelona Clinic Liver Cancer stage, Okuda stage, and Child-Pugh classification (Harrell's concordance index = 0.614). Taken together, these findings suggest that protocadherin 20 may represent a novel prognostic biomarker for HCC patients.

Citing Articles

ZNF714 Supports Pro-Oncogenic Features in Lung Cancer Cells.

Oleksiewicz U, Machnik M, Sobocinska J, Molenda S, Olechnowicz A, Florczak A Int J Mol Sci. 2023; 24(21).

PMID: 37958512 PMC: 10649060. DOI: 10.3390/ijms242115530.

Identification of long non-coding RNAs and RNA binding proteins in breast cancer subtypes.

Cava C, Armaos A, Lang B, Tartaglia G, Castiglioni I Sci Rep. 2022; 12(1):693.

PMID: 35027621 PMC: 8758778. DOI: 10.1038/s41598-021-04664-z.

Do Protocadherins Show Prognostic Value in the Carcinogenesis of Human Malignant Neoplasms? Systematic Review and Meta-Analysis.

Dutra T, Bezerra T, Luna E, Carvalho F, Chaves F, Barros Silva P Asian Pac J Cancer Prev. 2020; 21(12):3677-3688.

PMID: 33369468 PMC: 8046292. DOI: 10.31557/APJCP.2020.21.12.3677.

Identification and validation of a ten-gene set variation score as a diagnostic and prognostic stratification tool in hepatocellular carcinoma.

Zou C, Yuan C, Ye J, Liu Z, Gao X, Piao X Am J Transl Res. 2020; 12(9):5683-5695.

PMID: 33042448 PMC: 7540149.

Long non‑coding RNA‑based risk scoring system predicts prognosis of alcohol‑related hepatocellular carcinoma.

Luo Y, Ye J, Wei J, Zhang J, Li Y Mol Med Rep. 2020; 22(2):997-1007.

PMID: 32468063 PMC: 7339747. DOI: 10.3892/mmr.2020.11179.

References

Ning S, Bin C, Na H, Peng S, Yi D, Xiang-hua Y . Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep. 2011; 39(1):351-7. DOI: 10.1007/s11033-011-0745-y. View

Wang H, Chao K, Ng S, Bai A, Yu Q, Yu J . Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease. Genome Biol. 2016; 17:58. PMC: 4815271. DOI: 10.1186/s13059-016-0901-8. View

Fu S, Qi C, Xiao W, Li S, Peng B, Liang L . Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery. 2013; 154(3):536-44. DOI: 10.1016/j.surg.2013.02.014. View

EDMONDSON H, STEINER P . Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7(3):462-503. DOI: 10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e. View

Liu Y, Wang X, Jiang K, Zhang W, Dong J . The diagnostic value of tumor biomarkers for detecting hepatocellular carcinoma accompanied by portal vein tumor thrombosis. Cell Biochem Biophys. 2014; 69(3):455-9. DOI: 10.1007/s12013-014-9817-7. View

Chen Y, Xiang H, Zhang Y, Wang J, Yu G . Loss of PCDH9 is associated with the differentiation of tumor cells and metastasis and predicts poor survival in gastric cancer. Clin Exp Metastasis. 2015; 32(5):417-28. DOI: 10.1007/s10585-015-9712-7. View

Fang S, Huang S, Cao J, Wen Y, Zhang L, Ren G . Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression. Clin Exp Med. 2012; 13(2):127-34. DOI: 10.1007/s10238-012-0182-9. View

Yang Y, Jiang Y, Jiang M, Zhang J, Yang B, She Y . Protocadherin 10 inhibits cell proliferation and induces apoptosis via regulation of DEP domain containing 1 in endometrial endometrioid carcinoma. Exp Mol Pathol. 2016; 100(2):344-52. DOI: 10.1016/j.yexmp.2016.03.002. View

Lin Y, Wang Y, Fu X, Ma J . Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma. Med Sci Monit. 2014; 20:2380-5. PMC: 4251547. DOI: 10.12659/MSM.892433. View

10.

Lin Y, Wang Y, Ma J, Li W . Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer. J Exp Clin Cancer Res. 2015; 33:68. PMC: 4237820. DOI: 10.1186/s13046-014-0068-7. View

11.

Chen T, Long B, Ren G, Xiang T, Li L, Wang Z . Protocadherin20 Acts as a Tumor Suppressor Gene: Epigenetic Inactivation in Nasopharyngeal Carcinoma. J Cell Biochem. 2015; 116(8):1766-75. DOI: 10.1002/jcb.25135. View

12.

Lin Y, Deng Q, Wang Y, Fu X, Ma J, Li W . Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy. Med Sci Monit. 2015; 21:3955-690. PMC: 4689382. DOI: 10.12659/msm.896763. View

13.

Zhang C, Peng Y, Yang F, Qin R, Liu W, Zhang C . PCDH8 is Frequently Inactivated by Promoter Hypermethylation in Liver Cancer: Diagnostic and Clinical Significance. J Cancer. 2016; 7(4):446-52. PMC: 4749365. DOI: 10.7150/jca.13065. View

14.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

15.

Zhang S, Zhong B, Chen M, Yang L, Yang G, Li Y . Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells. Int J Cancer. 2013; 134(7):1583-94. DOI: 10.1002/ijc.28487. View

16.

Qiu C, Bu X, Jiang Z . Protocadherin-10 acts as a tumor suppressor gene, and is frequently downregulated by promoter methylation in pancreatic cancer cells. Oncol Rep. 2016; 36(1):383-9. DOI: 10.3892/or.2016.4793. View

17.

Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F . Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res. 2006; 66(9):4617-26. DOI: 10.1158/0008-5472.CAN-05-4437. View

18.

Dang Z, Shangguan J, Zhang C, Hu P, Ren Y, Lv Z . Loss of protocadherin-17 (PCDH-17) promotes metastasis and invasion through hyperactivation of EGFR/MEK/ERK signaling pathway in hepatocellular carcinoma. Tumour Biol. 2015; 37(2):2527-35. DOI: 10.1007/s13277-015-3970-5. View

19.

Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S . Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology. 2002; 36(2):427-32. DOI: 10.1053/jhep.2002.34852. View

20.

Kanai Y . Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci. 2009; 101(1):36-45. PMC: 11159222. DOI: 10.1111/j.1349-7006.2009.01383.x. View